Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.69 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | CASP1 | P29466 | 3/20 | 0.43 |
| ▸ | CASP7 | P55210 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7939316 | 0.83 | CYP11B1 (0.69) | CYP11B1CYP11B2KDM4EALDH1A1HPGD | |
| SCHEMBL1605619 | 0.83 | CYP11B1 (0.69) | CYP11B1CYP11B2CYP19A1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1605508 | 0.82 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP19A1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1606498 | 0.82 | CYP11B1 (0.68) | CYP11B1CYP11B2KDM4EALDH1A1HPGD | |
| SCHEMBL2792363 | 0.82 | CYP11B2 (1.00) | CYP11B1CYP11B2CYP19A1KDM4EALDH1A1 | |
| SCHEMBL5194088 | 0.82 | NR1I2 (0.51) | CYP11B1CYP11B2NR1I2KDM4EALDH1A1 | |
| SCHEMBL1120892 | 0.81 | CYP11B2 (0.66) | CYP11B1CYP11B2CYP19A1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1604935 | 0.81 | CYP11B2 (0.97) | CYP11B1CYP11B2CYP19A1KDM4EALDH1A1 | |
| SCHEMBL2789460 | 0.79 | CYP11B1 (0.67) | CYP11B1CYP11B2CYP3A4TLR9CYP2D6 | |
| SCHEMBL28383145 | 0.79 | NR1I2 (0.58) | NR1I2KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935882-B1 | Bicyclic compounds | ASAHI KASEI PHARMA CORP (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-7598284-B2 | Indazole compounds as B3 adrenoceptor agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7511069-B2 | Indazole compounds as β3 andrenoceptor agonist | ASAHI PHARMA CORPORATION (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1447400-B1 | BICYCLIC COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1935882-A1 | Bicyclic compounds | Asahi Kasei Pharma Corporation (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | ASHI KASEI PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-01-17 | — | — | US | disclosed |
| CN-100347158-C | Bicyclic compounds | ASAHI CHEMICAL IND (JP) | 2007-11-07 | — | — | CN | disclosed |
| US-7271190-B2 | Indazole compounds as β3 adrenoceptor agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-09-18 | — | — | US | disclosed |
| CN-1606544-A | Bicyclic compounds | ASAHI CHEMICAL IND (JP) | 2005-04-13 | — | — | CN | disclosed |
| US-20050020602-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1447400-A1 | BICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020602-A1 | Bicyclic compound | GOT1, H1-0, HSD11B1 | CYP11B1 9/4885CYP11B2 22/4885CYP19A1 59/4885 |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | OPRL1, NPBWR1, NPY4R | CYP11B1 325/4885CYP11B2 251/4885CYP19A1 1328/4885 |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ADRB3, ADRB2, OPRD1 | CYP11B1 342/4885CYP11B2 282/4885CYP19A1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.